Projets Industriels

  1. Etudes industrielles à venir:

Etudes Porteur de projets Titres
Vaccin VRS MSD A phase II, randomised, observer-blind, controlled, multi-country study to "rank" different formulations based on immunogenicity, reactogenicity and safety of GSK Biologicals' investigational RSV vaccine GSK3003891A, to healthy women, aged 18-45 years.
GRIPPE Sanofi MSD A phase 2b, multicenter, randomizedn double-blind, controlled study to evaluate the efficacy and safety of study drug administered intravenously in addition to Oseltamivir compared with Oseltamivir alone in hospitalized adults with influenza a infection requiring oxygen support.

 

  1. Etudes industrielles en cours de réalisation:
Etudes Porteur de projets Centres Titres
OPAL (JNJ 63623872) GSK Cochin, St Etienne, Bichat, CRC de Lyon, Tours, St Louis et Limoges A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the
Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection
EBOVAC (VAC 52150) Janssen Research & Development Cochin, Rennes, URCI de Lyon, Tours, St Etienne et Strasbourg A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate
Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults in
Europe
STRIVE (B3451002) Sanofi Pasteur Cochin, Dijon, Rennes, St-Etienne, Strasbourg et Nîmes.  A Phase 2b, Randomized, Double-blind, Placebo-controlled Study To Evaluate The Safety And Efficacy Of Staphylococcus Aureus 4-antigen Vaccine (sa4ag) In Adults Undergoing Elective Posterior Instrumented Lumbar Spinal Fusion Procedures
H030-034 CDIFF Sanofi Pasteur Dijon, Annecy, Lille, Cochin, St-Etienne, Clermont-Ferrand, Tours, Limoges, Bichat, Montpellier et CRC Lyon. Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Vaccine in Subjects at Risk for C. difficile Infection
RHEIA-VAC HPV (PC10VAC02) GSK

Dijon, Lyon, Lille, Nîmes, Strasbourg, Besançon et Clermont-Ferrand.

A Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate ProCervix Efficacy to Clear HPV 16 and HPV 18 Infection in Women With Normal Cytology or ASCUS/LSIL
THV01-11-01 Theravectys

Cochin, St-Etienne, St-Louis, Rennes, Clermont-Ferrand,  Dijon, Strasbourg, Nancy et CRC de Lyon.

A multi‐center, randomized, double‐blind, placebo‐controlled Phase I/II
trial to compare the safety, tolerability and immunogenicity of the therapeutic THV01 vaccination at 5.106 TU, 5.107 TU or 5.108 TU doses to placebo in HIV‐1 clade B infected patients under highly active antiretroviral therapy (HAART).
TG-4010 Transgène Limoges, Lille, Clermont-Ferrand, St-Etienne et Besançon. A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC).
V212-011 Merck & Co. Bichat, Clermont-Ferrand, Cochin, Limoges, Montpellier, Rennes, St-Etienne et St-Louis. A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy.
VRS F-021 GSK Cochin et Clermont-Ferrand Vaccin anti-VRS chez des femmes volontaires saines de 18 à 45 ans

 

Français